kaiser semaglutide criteria Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial 📌 Starting January 1, 2025,

In a first multicentered real-world study assessing the weight loss and metabolic outcomes of semaglutide, we demonstrated effective weight-loss outcomes and associated comorbidity profile improvement in patients with overweight or obesity, Wissam Ghusn, MD, a postdoctoral research fellow in the Precision Medicine for Obesity Program at the Mayo Clinic in Rochester, Minnesota, told Healio

This is in line with clinical guidelines for healthy, lasting weight loss

A.NedosugovaL

The results revealed that two hydrazides (HBH and 3-HNAH) and two hydrazine reagents (2-HQ and DNPH) could effectively react with the carbonyl groups of gaseous aldehydes (such as formaldehyde, acetaldehyde, and propionaldehyde)